Everett Cunningham is VP at QUEST DIAGNOSTICS INC (DGX). They have made 10 open-market trades across 2 companies since 2016, most recently 2026-06-24.
CIK 0001564777
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EXAS | SELL · 10b5-1 | 2024-05-01 | 2024-05-02 | $60.15 | $8K | -13.6% | -28.3% | -26.9% |
| EXAS | SELL · 10b5-1 | 2024-03-01 | 2024-03-04 | $59.32 | $286K | +0.1% | +24.5% | -23.4% |
| EXAS | SELL · 10b5-1 | 2024-02-27 | 2024-02-28 | $56.89 | $415K | +6.4% | +23.4% | -17.6% |
| EXAS | SELL · 10b5-1 | 2024-02-22 | 2024-02-23 | $59.78 | $81K | -1.3% | +11.8% | -5.2% |
| EXAS | SELL | 2023-10-12 | 2023-10-13 | $66.49 | $1.7M | -4.7% | -8.6% | +5.9% |
| EXAS | SELL | 2023-03-01 | 2023-03-02 | $62.01 | $450K | -0.5% | +3.0% | +25.9% |
| EXAS | SELL | 2022-10-12 | 2022-10-13 | $31.37 | $1.1M | +7.9% | +44.8% | +117.1% |
| DGX | SELL | 2019-03-04 | 2019-03-05 | $86.81 | $676K | +3.8% | +6.8% | +12.9% |
| DGX | SELL | 2019-02-26 | 2019-02-28 | $86.58 | $229K | -0.4% | +3.4% | +11.0% |
| DGX | SELL · 10b5-1 | 2019-02-25 | 2019-02-27 | $88.23 | $29K | -0.7% | +4.5% | +12.8% |
| DGX | SELL | 2018-07-10 | 2018-07-12 | $112.00 | $4.5M | -7.4% | -4.7% | -9.2% |
| DGX | SELL | 2018-07-02 | 2018-07-05 | $109.69 | $11.3M | +3.4% | -1.7% | -3.7% |
| DGX | SELL | 2016-05-09 | 2016-05-11 | $76.26 | $4.3M | -0.3% | +1.5% | +12.1% |
| DGX | SELL | 2016-05-09 | 2016-05-11 | $76.26 | $8.6M | -0.3% | +1.5% | +12.1% |
| DGX | SELL | 2016-05-06 | 2016-05-09 | $76.00 | $3.8M | -0.6% | +2.9% | +10.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.